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concurrently. There was no significant difference regarding 
anemia and B19 infection in either group. All B19 isolates 
were clustered in genotype 1A.  Conclusion: Our findings in-
dicate that B19 infection plays no role in leading chronic ane-
mia in dialysis patients. However, persistent B19 viremia and 
the circulation of the same strains in dialysis patients may 
indicate a potential risk for the contamination of dialysis 
equipment and nosocomial spread of B19 infection within 
dialysis units.  © 2017 S. Karger AG, Basel 
 Introduction 
 Parvovirus B19 (B19) is a small nonenveloped single-
stranded DNA virus belonging to the Parvoviridae fam-
ily and Parvovirinae subfamily  [1] . Respiratory spread 
appears to be the most common route of B19 transmis-
sion and the virus is easily transmitted with close contact 
but can also be acquired through blood and blood prod-
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 Abstract 
 Objectives: The aim of this study was to evaluate the fre-
quency and genotype of human parvovirus B19 and its rela-
tion with anemia among Iranian patients under dialysis. 
 Methods: Fifty hemodialysis (HD) and 33 peritoneal dialysis 
(PD) patients were enrolled. B19 IgG and IgM antibodies 
were assessed by ELISA, and the presence of B19 DNA was 
evaluated by nested PCR. PCR products were sequenced di-
rectly and phylogenetic analysis was performed.  Results: In 
the HD group, the prevalence of B19 antibodies was 54% for 
IgG and 4% for IgM. B19 DNA was detected in 10% of the 
cases, and 10% showed B19 IgG and viremia simultaneously. 
In the PD group, the prevalence of B19 IgG and IgM was 57.6 
and 0% respectively, whereas B19 DNA was found in 12.1% 
of the group. A total of 9.1% showed B19 IgG and viremia 
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ucts. The vertical route of transmission from mother to 
fetus and nosocomial transmission of the virus have also 
been documented  [2, 3] . 
 In immunocompetent subjects, acute B19 infection is 
usually mild and associated with transient anemia, ar-
thritis, and rash. It was shown that after acute B19 infec-
tion, B19 DNA remains in bone marrow, kidney, liver, 
myocardium, and other organs  [4–6] . In contrast, in im-
munosuppressed cases, acute B19 infection may be as-
sociated with severe symptoms. Generally, solid organs 
or stem cell recipients are at increased risk for viral re-
activation that may originate from a persisting previous 
viral infection or from transmitted pathogens through 
the transplantation  [7] . Due to notable tropism of B19 
to human bone marrow and erythroid precursor cells 
for replication, anemia is considered the main complica-
tion of B19 infection  [8] . B19 infection can also cause 
aplastic crisis in patients with chronic hemolytic ane-
mia.
 Patients with renal failure on dialysis have disrup-
tions in their immune system due to the immunosup-
pressive effects of uremia, deficient erythropoietin pro-
duction, and significantly decreased erythrocyte surviv-
al  [9, 10] . Therefore, dialysis patients reveal increased 
susceptibility to acute and chronic anemia after B19 in-
fection. Moreover, B19 infection can induce aplastic cri-
sis in dialysis patients similar to hemolytic anemia cases 
 [11] . On the other hand, some authors believe that 
erythropoietin administration during B19 infection can 
facilitate viral replication  [12] . Nosocomial spread of in-
fection in the dialysis unit is also a potential threat, al-
though this is not well explained in the literature  [3] . 
Finally, persistent B19 infection in patients on chronic 
dialysis could be clinically symptomatic after renal 
transplantation and the consumption of immunosup-
pressants  [13] . Therefore, it seems that B19 infection in 
dialysis patients can be noticeable. Nowadays, persistent 
B19 infection has a special significance and is of great 
interest in different settings, including dialysis patients 
 [14–18] .
 Three distinct genotypes of B19 have been described: 
genotype 1, with subtypes 1A and 1B, genotype 2, and 
genotype 3, with subtypes 3A and 3B  [19, 20] . Available 
data show some geographical restrictions for B19 geno-
types. Genotype 1 is the most common B19 genotype de-
tected worldwide, while genotype 2 has been reported 
from western countries like Germany  [21] , Finland  [22] , 
the USA and Brazil  [23, 24] . Genotype 3 has been restrict-
ed to samples from French and Brazilian patients and 
Ghanaian blood donors  [19, 24, 25] . 
 However, there are insufficient data regarding the dis-
tribution and molecular epidemiology of B19 in dialysis 
patients, while this population may be vulnerable to ane-
mia due to B19 infection. We therefore aimed to evaluate 
the frequency of B19 in Iranian hemodialysis (HD) and 
peritoneal dialysis (PD) patients, and to explore their 
molecular characterization as well as its relation to ane-
mia.
 Patients and Methods 
 Study Population 
 In this cross-sectional study, 83 dialyzed patients (50 on HD 
and 33 on PD) who were referred to the main dialysis units of 
Tehran, Iran, were consecutively enrolled in the study from Sep-
tember 2014 to November 2014. A questionnaire was provided to 
collect epidemiological and clinical data such as age, gender, 
length of time on dialysis, and previous medical history. The study 
protocol was approved by the ethical committee of the Iranian 
Society for Support of Patients with Infectious Diseases and in-
formed consent was obtained from all patients. Anemia in dialysis 
patients has been defined by the World Health Organization  [26] 
as a hemoglobin concentration <13.0 g/dL for adult males and 
postmenopausal women, and <12.0 g/dL for premenopausal 
women.
 Serological Assessment 
 All plasma samples were tested for B19 virus-specific antibod-
ies using enzyme-linked immunosorbent assay (ELISA) kits for 
the detection of B19 IgG and IgM antibodies (EUROIMMUN, Lü-
beck, Germany). These assays were performed according to the 
protocols provided by the manufacturer. The serum hepatitis B 
surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), 
and hepatitis C antibody (anti-HCV) levels were also detected by 
ELISA. The commercial enzyme immunoassay kits used were 
from Dia.Pro Diagnostic BioProbes (Milan, Italy). Human immu-
nodeficiency virus (HIV) infection was diagnosed by ELISA (MP 
Biomedicals, Illkirch, France) with confirmatory Western blot 
analysis (Diaplus, San Francisco, CA, USA). 
 DNA Extraction and PCR 
 B19-DNA was extracted from 200 μL of plasma using the RTP 
DNA/RNA Virus Mini Kit (Invitek, Berlin, Germany) according 
to manufacturer’s instructions. The extracted DNA was stored at 
–20  °  C before PCR analysis.
 In order to evaluate the suitability of extracted DNA, β-globin 
gene amplification was performed using PCO3 (5 ′ -ACACAACT-
GTGTTCACTAGC-3 ′ ) and PCO4 (5 ′ -CAACTTCATCCACGT-
TCACC-3 ′ ) primers which amplify a 110-bp fragment. PCR was 
carried out in a 25-μL amplification mixture containing 1 μL of 
extracted DNA, 1.5 m M of MgCl 2 , 15 m M of Tris-HCl (pH 8.0), 0.2 
m M of dNTP, 50 m M of KCl, 10 pmol of each primer, and 1.5 U 
of Taq polymerase (YTA PCR Master Mix). β-Globin-positive 
samples were subjected to nested PCR.
 A fragment of the DNA sequence coding for the major capsid 
protein (VP2) of parvovirus B19 was amplified by nested PCR. 
The first round of PCR was carried out using the primer pair TJI 
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(5 ′ -TTCTTTTCAGCTTTTAGG-3 ′ [nucleotides 3775–3792]) 
and R4154 (5 ′ -TATTCCTGTGACATATTT-3 ′ [nucleotides 
4171–4154]), which were described previously by Melon et al. 
 [27] . The first round of PCR was performed with 10 μL of DNA 
extract added to an amplification mixture containing 2.5 μL of 
10× PCR buffer, 1 μL of MgCl 2 , 0.75 μL of dNTP mix, 0.4 μL of 
Taq polymerase, 1 μL of each primer in a total volume of 15 μL 
(8.35 μL of distilled water). The PCR profile was an initial 5 min 
denaturation at 94  °  C, followed by 35 cycles of amplification, in-
cluding denaturation for 30 s at 94  °  C, annealing for 40 s at 45  °  C, 
and extension for 50 s at 72   °   C. Strand synthesis was completed 
at 72   °   C for 10 min and stored in 4   °   C for 5 min. A total of 2 μL 
of the first-round PCR products was then subjected for the sec-
ond-round PCR under the same conditions but with the primers 
TJ2 (5 ′ -TATAAGTTTCCTCCAGTGCC-3 ′ [nucleotides 3818–
3837]) and TJII (5 ′ -TGAATTGCATGGTCTTCATG-3 ′ [nucle-
otides 3975–3956]) in a total volume of 23 μL of amplification 
mixture (16.35 μL of distilled water).The expected size of the 
second PCR product was 158 bp. Each batch included negative 
controls containing water and B19 plasmids as positive controls. 
The PCR products were electrophoresed on a 1.5% agarose gel 
with the 100-bp DNA ladder (SinaClon, Tehran, Iran), stained 
with ethidium bromide, and visualized by ultraviolet transillu-
mination.
 DNA Sequencing, Genotyping and Phylogenetic Analysis 
 Nested PCR products were purified using the QIAquick PCR 
purification kit (Qiagen, Hilden, Germany) and then sequenced 
directly for both directions at Pishgam Biotech Company (Tehran, 
Iran) using the Sanger method. The phylogenetic analysis was 
based on B19 VP2 sequences of the patients described in this study 
and reference sequences of various B19 subtypes downloaded from 
the GenBank database.
 Nucleotide sequences were aligned using the CLUSTAL W 
program in CLC Main Workbench 6.5 software (CLC Bio, Qia-
gen). The genetic distance was calculated using the Kimura 2-pa-
rameter matrix. A phylogenetic tree was subsequently constructed 
by the neighbor-joining method and tested with the bootstrap 
resamplings (1,000 replicates) using the MEGA program, version 
5. The B19 sequences obtained in this study were deposited in the 
GenBank under accession No. KU891254-62.
 Statistical Analysis 
 Statistical analyses were conducted using SPSS statistics soft-
ware (version 16, Chicago, IL, USA). The χ 2 test or Fisher exact test 
was used to compare variables. Data are presented as the mean ± 
SD or, when indicated, as an absolute number and percentage.  p 
values <0.05 were considered statistically significant.
 Results 
 A total of 50 patients on HD (mean age 53.18 ± 16.44 
years) and 33 patients on PD (mean age 53.66 ± 13.02 
years) were enrolled in the study. The overall prevalence 
of B19-specific IgG in patients under dialysis was 55.4% 
(46 of 83) and of B19 IgM was 2.4% (2 of 83). B19 DNA 
was detected in 10.8% (9 of 83) of cases. One sample was 
positive for both antibodies, while 8 cases (9.64%) re-
vealed B19 IgG and viremia concurrently. The mean Hb 
in HD and PD patients was 10.51 ± 1.57 and 11.23 ± 2.1 
g/dL, respectively. Anemia was found in 86.74% of dialy-
sis patients. Erythropoietin (EPO) was received by 60.2% 
cases. All HD patients were negative for HBsAg, anti-
HBc, and anti-HIV. One HD patient had anti-HCV.
 In the HD group, 38% were male and 62% were female. 
The mean duration of dialysis was 56.58 ± 52.46 months 
and the dialysis interval was 3 times a week. The preva-
lence of B19-specific immunoglobulin was 54% (27 of 50) 
for IgG and 4% (2 of 50) for IgM. The prevalence of B19 
viremia was 10% (5 out of 50) in HD subjects. One sample 
was found to be positive for both antibodies, while 5 cas-
es (10%) showed B19 IgG and viremia simultaneously. 
Anemia was present in 92% of the HD cases. In the pres-
ent study, we did not observe a significant relation be-
tween the presence of B19 IgG, IgM and viremia and age, 
sex, mean duration of dialysis, and anemia. 
 In the PD group, 54.5% were male and 45.5% were fe-
male, and the mean duration of dialysis was 38.94 ± 35.21 
months. The prevalence of B19 IgG and IgM was 57.6% (19 
of 33) and 0% respectively, whereas B19 DNA was found 
in 12.1% (4 of 33) of this group. Three cases (9.1%) showed 
B19 IgG and viremia concurrently. Anemia was present in 
78.8% of the PD patients. We did not find any significant 
relation between the presence of B19 IgG, IgM and viremia 
and age, sex, mean duration of dialysis, and anemia. 
 No significant difference between the PD and HD 
groups was found regarding B19 IgG, IgM, and viremia. 
 Table 1 summarizes the ELISA and PCR results in the 2 
groups.
 Table 1.  ELISA and PCR results in HD and PD patients
Dialysis patients B19 IgM,
n (%)
B19 IgG,
n (%)
B19 DNA,
n (%)
B19 IgM + IgG,
n (%)
B19 IgG + B19 DNA,
n (%)
HD (n = 50) 2 (4) 27 (54) 5 (10) 1 (2) 5 (10)
PD (n = 33) 0 (0) 19 (57.6) 4 (12.1) 0 (0) 3 (9.1)
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AY647977 B19 Br543 genotype 3B
AY083234 B19 D91.1 genotype 3B
DQ234779 B19 R0748 genotype 3B
DQ234778 B19 R0693 genotype 3B
AY582124 B19 Gh2768 genotype 3B
DQ408304 B19 BN60.3 genotype 3B
DQ408303 B19 BN59.3 genotype 3B
DQ234771.2 B19 R0227 genotype 3A
DQ234769.2 B19 R0416 genotype 3A
AY582125.2 B19 Gh3051 genotype 3A
NC 004295.1 human erythrovirus V9
AJ249437 human erythrovirus V9
AX003421 B19 genotype 3A
DQ333427.1 B19 BN32.2 genotype 2
DQ333428.1 B19 BN33 genotype 2
AY064476.1 B19 genotype 2
AY064475.1 B19 genotype 2
AY044266 B19 LaLi genotype 2
DQ333426.1 B19 BN31.2 genotype 2
DQ357065.1 B19 genotype 1B
DQ357064 B19 genotype 1B
DQ225151 B19 genotype 1A
DQ408301 B19 genotype 1A
Z68146 B19 genotype 1A
AF162273.1 B19 genotype 1A
M13178 B19-Au genotype 1A
IR-4
IR-1
AY504945.1 B19 genotype 1A
IR-6
ref. NC 000883.2 B19 genotype 1A
IR-5
IR-2
IR-3
IR-8
IR-7
IR-90.02
51
68
89
94
71
83
99
51
51
30
32
46
9
17
14
4913
94
91
90
93
50
99
60
49
45
43
66
71
 Fig. 1. Phylogenetic tree from the B19 VP2 region of 9 human parvovirus B19 strains isolated from Iranian HD 
and PD patients. Reference sequences for 1A, 1B, 2, 3A, and 3B subtypes from the GenBank database were also 
included. The numbers next to the nodes of the tree represent bootstrap values (1,000 replicates). The Iranian 
sequences determined in this study are indicated by the IR prefix. IR-1 to 4 relate to PD patients and IR-5 to 9 
were isolated from the HD group. 
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 Phylogenetic analysis revealed that all B19 isolates in 
the PD and HD groups clustered to genotype 1, and were 
classified as subtype B19-1A ( Fig. 1 ). We also identified 
the nucleotide and amino acid divergence in our isolates. 
Comparing the nucleotide sequences revealed the overall 
variation to be 0.10879 (range 0.00–0.19990). The mean 
intragenotypic nucleotide distance within Iranian iso-
lates and other 1A isolates was 0.01167 (range 0.000–
0.03267). The mean variation between Iranian strains was 
0.00848 and the maximum distance was 0.01924. 
 By comparison of the amino acid sequences, the over-
all variation was 0.30818 (range 0.00–0.5877). The mean 
intragenotypic amino acid distance within Iranian iso-
lates and other 1A isolates was 0.03154 (range 0.000–
0.08894). The mean variation between Iranian strains was 
0.02405 and the maximum distance was 0.06596.
 According to  Figure 1 and the genetic distance analysis 
on isolates detected from the PD center, IR-1 and IR-4 
were the same, while IR-2 and IR-3 had a similar genetic 
distance and fell in another branch of the phylogenetic 
tree. This suggests that 2 different B19 isolates are circu-
lating in our PD center. Regarding isolates recovered 
from 1 HD center, IR-8 and IR-9 clustered in 1 branch of 
the phylogenetic tree, which may indicate that these iso-
lates are similar, while IR-7 from the same dialysis center 
revealed some genetic distance (0.02151) but was close to 
IR-8 and IR-9. Moreover, IR-5 and IR-6, which were ob-
tained from another HD center, showed minimal genetic 
distance, demonstrating that they are only close to each 
other. 
 Discussion 
 This is the first report to investigate the serological 
and molecular characterization of parvovirus B19 in pa-
tients on HD and PD in Iran. The prevalence of B19-
specific immunoglobulin was 54% for IgG and 4% for 
IgM, and B19 viremia was found in 10% of HD subjects, 
while 10% of HD cases showed B19 IgG and viremia si-
multaneously. In the PD group, the prevalence of B19 
IgG and IgM was 57.6 and 0% respectively, whereas B19 
DNA was found in 12.1%. B19 IgG and viremia was con-
currently shown in 9.1% of PD cases. Moreover, in the 
present study we did not observe a significant relation 
between the presence of B19 IgG, IgM, and viremia and 
anemia in both groups. 
 Anemia is common in patients with chronic kidney 
disease under dialysis  [28] but the morbidity and mortal-
ity mainly depend on the etiology of anemia and the stage 
of renal disease  [29] . The significance of B19 infection in 
patients with chronic renal failure remains to be clarified. 
Patients undergoing dialysis may have increased suscep-
tibility to acute and chronic anemia after B19 infection. 
The immunosuppression state in dialysis patients due to 
underlying diseases and immunosuppressive treatment 
may prevent an effective antiviral immune response relat-
ing to persistent viral infection and chronic suppression 
of erythropoiesis with the development of chronic ane-
mia or B19-related recurrent anemia  [30, 31] . Potentially 
life-threatening transient aplastic crisis due to B19 infec-
tion is also a major concern in some dialysis cases  [11] . 
Finally, persistent B19 infection in patients on chron-
ic dialysis can become clinically manifested after renal 
transplantation and the administration of immunosup-
pressive medications  [13] . 
 Previous investigations have described the B19 distri-
bution in different settings and shown a variable epide-
miological pattern among populations  [32–35] . Howev-
er, most surveys mainly focused on the prevalence of B19 
in kidney transplant subjects, and few studies have been 
carried out on the B19 frequency in dialysis patients. In a 
study by Małyszko et al.  [32] , B19 IgM and IgG antibodies 
were detected in 16 and 49% of dialyzed patients, respec-
tively. There were no significant differences among dia-
lyzed patients with and without acute or chronic B19 in-
fection regarding Hb, erythrocyte count, and erythropoi-
etin concentration. 
 In a study on 62 hemodialyzed patients, Guiserix et al. 
 [36] reported that B19 infections play no role in leading 
chronic anemia in these subjects. Moreover, there was no 
correlation between time on dialysis and IgG antibodies. 
 Alves et al.  [29] conducted a survey on 120 dialyzed 
patients (106 on HD and 14 on PD) and showed that the 
overall B19 seroprevalence was 67.5%. There was no sig-
nificant correlation between B19 infection and anemia. 
They suggested that B19 infection creates little problem 
in dialyzed patients. 
 We previously carried out a study on HIV patients and 
a control group  [35] . The prevalence of B19 IgG, IgM, and 
DNA in the control group was 25, 1.6, and 9.4%, respec-
tively, while in the HIV group the prevalence of IgG, IgM, 
and B19 DNA was 11.1, 1, and 13.1%, respectively. B19 
IgG and viremia was simultaneously shown in 3% of HIV 
cases. In comparison with the present study, we reported 
a higher rate of IgG, IgM, and B19 DNA, and concurrent 
presence of IgG and viremia. Therefore, the prevalence of 
parvovirus B19 is very variable and the degree of immu-
nodeficiency can explain the differences in the IgG se-
roprevalence and viremia found in different studies. It 
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seems that dialysis patients have no problem in produc-
ing B19 antibodies in accordance with our results, while 
some studies have reported low rates of B19 IgG among 
HIV patients due to underlying immunological problems 
 [34, 35] . However, persistent B19 infection with coexist-
ing IgG and viremia was found commonly in our HD 
cases, possibly due to a qualitative defect of antibodies for 
neutralizing the virus  [37, 38] . The clinical significance of 
B19 infection in patients undergoing dialysis is not clear, 
but persistent B19 viremia should be considered a poten-
tial risk through the contamination of dialysis equipment 
and subsequent threat to dialysis patients during trans-
plantation procedures. 
 In agreement with other reports from most parts of the 
world, including Iran, genotype 1A was the only detect-
able genotype in this study group. In our survey, a low 
degree of nucleotide diversity among B19 strains was de-
tected, which concurs with other reports (<2%)  [39] . 
However, in comparison to our previous study conducted 
in HIV patients and normal controls, we report a higher 
degree of nucleotide diversity in samples isolated from 
dialysis patients. Moreover, we have identified the same 
strains isolated from 1 dialysis center, revealing the pos-
sibility of nosocomial spread of B19 infection among di-
alysis patients. There are limited studies on this issue, al-
though Ozeki et al.  [3] described 1 HD case with transient 
aplastic crisis due to nosocomial B19 infection.
 In conclusion, this study investigated the serological 
and molecular characterization and importance of parvo-
virus B19 infection in patients under dialysis in Iran. Our 
findings indicate that B19 infection plays no role in lead-
ing chronic anemia in dialysis patients. However, persis-
tent B19 viremia and the circulation of the same strains 
in dialysis patients may demonstrate a potential risk for 
the contamination of dialysis equipment and nosocomi-
al spread of B19 infection within dialysis units. Further 
studies with larger samples are required to clarify the nos-
ocomial spread of B19 infection in dialysis units as a po-
tential threat, which could be clinically symptomatic after 
renal transplantation. 
 Acknowledgements 
 The authors are grateful to the Iranian Society for Support of 
Patients with Infectious Disease for financial support of this study. 
 Disclosure Statement 
 No conflicts of interest exist for any of the authors.
 
 References 
 1 Corcoran A, Doyle S: Advances in the biology, 
diagnosis and host-pathogen interactions of 
parvovirus B19. J Med Microbiol 2004; 53: 
 459–475. 
 2 Heegaard ED, Brown KE: Human parvovirus 
B19. Clin Microbiol Rev 2002; 15: 485–505. 
 3 Ozeki M, Fukushima T, Ohzeki M, Sasaki T, 
Kashihara N: A nosocomial parvovirus B19 
infection-induced transient aplastic crisis in 
a patient with chronic renal failure. Clin 
Nephrol 2006; 65: 141–143. 
 4 Tanawattanacharoen S, Falk RJ, Jennette JC, 
Kopp JB: Parvovirus B19 DNA in kidney tis-
sue of patients with focal segmental glomeru-
losclerosis. Am J Kidney Dis 2000; 35: 1166–
1174. 
 5 Corcioli F, Zakrzewska K, Rinieri A, Fanci R, 
Innocenti M, Civinini R, De Giorgi V, Di Lol-
lo S, Azzi A: Tissue persistence of parvovirus 
B19 genotypes in asymptomatic persons. J 
Med Virol 2008; 80: 2005–2011. 
 6 Schenk T, Enders M, Pollak S, Hahn R, Huzly 
D: High prevalence of humanparvovirus B19 
DNA in myocardial autopsy samples from 
subjects without myocarditis or dilative car-
diomyopathy. J Clin Microbiol 2009; 47: 106–
110. 
 7 Plentz A, Würdinger M, Kudlich M, Modrow 
S: Low-level DNAemia of parvovirus B19 
(genotypes 1–3) in adult transplant recipients 
is not associated with anaemia. J Clin Virol 
2013; 58: 443–448. 
 8 Henriques I, Monteiro F, Meireles E, Cruz A, 
Tavares G, Ferreira M, Araújo F: Prevalence 
of parvovirus B19 and hepatitis A virus in 
Portuguese blood donors. Transfus Apher Sci 
2005; 33: 305–309. 
 9 Tolkoff-Rubin N, Rubin R: Uremia and host 
defenses. N Engl J Med 1990; 322: 770–772. 
 10 Vanholder R, Loo V, Dhondt AM, Smet RD, 
Ringoir S: Influence of uraemia and haemodi-
alysis on host defense and infection. Nephrol 
Dial Transplant 1996; 11: 593–598. 
 11 Duranay M, Bali M, Sahin M, Yakinci G, Vur-
gun N, Dilmen U: Parvovirus B19 infection 
and unresponsiveness to erythropoietin ther-
apy in haemodialysis patients. Nephrol Dial 
Transplant 1998; 13: 779–780. 
 12 Arzouk N, Snanoudj R, Beauchamp-Nicoud 
A, Mourad G, Charpentier B, Tchernia G, 
Durrbach A: Parvovirus B19-induced anemia 
in renal transplantation: a role for rHuEPO in 
resistance to classical treatment. Transpl Int 
2006; 19: 166–169. 
 13 Waldman M, Kopp JB: Parvovirus B19 and 
the kidney. Clin J Am Soc Nephrol 2007; 
 2(suppl 1):S47–S56. 
 14 Söderlund-Venermo M, Hokynar K, Niemin-
en J, Rautakorpi H, Hedman K: Persistence of 
human parvovirus B19 in human tissues. 
Pathol Biol (Paris) 2002; 50: 307–316. 
 15 Adamson-Small LA, Ignatovich IV, Laem-
merhirt MG, Hobbs JA: Persistent parvovirus 
B19 infection in non-erythroid tissues: pos-
sible role in the inflammatory and disease 
process. Virus Res 2014; 190: 8–16.  
 16 Kerr JR: A review of blood diseases and cyto-
penias associated with human parvovirus B19 
infection. Rev Med Virol 2015; 25: 224–240. 
 17 Aghakhani A, Mohraz M, Azadmanesh K, 
Moayedi-Nia S, Kazemimanesh M, Mamishi 
S, Banifazl M, Ramezani A: No evidence of 
persistent parvovirus B19 viremia among Ira-
nian patients with HIV after a 1-year follow-
up. Arch Virol 2016; 161: 1183–1187. 
D
ow
nl
oa
de
d 
by
: 
Ve
rla
g 
S.
 K
AR
G
ER
 A
G
, B
AS
EL
   
   
   
   
   
   
   
   
   
  
17
2.
16
.6
.9
3 
- 2
/6
/2
01
7 
3:
11
:0
8 
PM
 Parvovirus B19 in Dialysis Patients  Intervirology 2016;59:179–185 
DOI: 10.1159/000455124
185
 18 Nowalany-Kozielska E, Kozieł M, Domal-
Kwiatkowska D, Wojciechowska C, Jacheć W, 
Kawecki D, Tomasik A, Przywara-Chowaniec 
B, Węglarz L, Reichman-Warmusz E, Wojnicz 
R: Clinical significance of viral genome per-
sistence in the myocardium of patients with 
dilated cardiomyopathy. Intervirology 2015; 
 58: 350–356. 
 19 Servant A, Laperche S, Lallemand F, Marinho 
V, de SaintMaur G, Meritet JF, Garbarg-Che-
non A: Genetic diversity within human eryth-
roviruses identification of three genotypes. J 
Virol 2002; 76: 9124–9134. 
 20 Pereira RFA, Cubel Garcia RCN, Azevedo 
KLM, Setúbal S, Siqueira MAMT, Castro TX, 
Oliveira SA: Molecular characterization of 
human parvovirus B19 strains circulating in 
Niterói/RJ – Brazil. Virus Rev Res 2012; 
 17(suppl):158–159. 
 21 Liefeldt L, Plentz A, Klempa B, Kershaw O, 
Endres AS, Raab U, Neumayer HH, Meisel H, 
Modrow S: Recurrent high level parvovirus 
B19/genotype 2 viremia in a renal transplant 
recipient analyzed by real-time PCR for si-
multaneous detection of genotypes 1–3. J 
Med Virol 2005; 75: 161–169. 
 22 Hokynar K, Söderlund-Venermo M, Pesonen 
M, Ranki A, Kiviluoto O, Partio EK, Hedman 
K: A new parvovirus genotype persistent in 
human skin. Virology 2002; 302: 224–228. 
 23 Nguyen QT, Wong S, Heegaard ED, Brown 
KE: Identification and characterization of a 
second novel human erythrovirus variant, 
A6. Virology 2002; 301: 374–380. 
 24 Sanabani S, Neto WK, Pereira J, Sabino EC: 
Sequence variability of human erythroviruses 
present in bone marrow of Brazilian patients 
with various parvovirus B19-related hemato-
logical symptoms. J Clin Microbiol 2006; 44: 
 604–606. 
 25 Candotti D, Etiz N, Parsyan A, Allain JP: 
Identification and characterization of persis-
tent human erythrovirus infection in blood 
donor samples. J Virol 2004; 78: 12169–12178. 
 26 World Health Organization: WHO Essential 
Medicines Library – EMLib: Iron Deficiency 
Anemia. Geneva, WHO, 2004. 
 27 Melon S, Deona M, Grande JA, Laures AS, 
Gomez Hurtas E: Infección por parvovirus 
B19 en trasplante renal. Diagnóstico por de-
tección del genoma viral en sangre periférica. 
Nefrologia 2005; 25: 67–72. 
 28 Kazmi WH, Kausz AT, Khan S, Abichandani 
R, Ruthazer R, Obrador GT, Pereira BJ: Ane-
mia: an early complication of chronic renal 
insufficiency. Am J Kidney Dis 2001; 38: 803–
812. 
 29 Alves MT, Vilaça SS, Godoi LC, Rezende 
Júnior L, Carvalho Md, Silva Fde S, Gui-
marães FL, Fernandes AP, Dusse LM, Gomes 
KB: Parvovirus B19 (B19) and cytomegalovi-
rus (CMV) infections and anti-erythropoietin 
(anti-EPO) antibodies in patients on dialysis 
hyporesponsive to erythropoietin therapy. 
Clin Chim Acta 2014; 431: 52–57. 
 30 Rerolle JP, Morelop E, Hetal I, Peraldi MN, 
Mamzer-Bruneel MF, Kreis H: Parvovirus B-
19-related anemia after renal transplantation. 
Scand J Infect Dis 2004; 36: 513–516. 
 31 Kumar J, Shaver MJ, Abul-Ezz S: Long-term 
remission of recurrent parvovirus B19-asso-
ciated anemia in a renal transplant recipient 
induces by treatment with immunoglobulin 
and positive seroconversion. Transpl Infect 
Dis 2005; 7: 30–33. 
 32 Małyszko J, Hryszko T, Małyszko JS, Wol-
czyński S, Myśliwiec M: Parvovirus B19 infec-
tion and IGF system components in relation 
to erythropoiesis in dialyzed patients and kid-
ney transplant recipients. Transplant Proc 
2002; 34: 3211–3214. 
 33 He M, Zhu J, Yin H, Ke L, Gao L, Pan Z, Yang 
X, Li W: Human immunodeficiency virus/hu-
man parvovirus B19 co-infection in blood do-
nors and AIDS patients in Sichuan, China. 
Blood Transfus 2012; 10: 502–514.  
 34 Lee YM, Chuang SY, Wang SF, Lin YT, Chen 
YM: Epidemiology of human herpesvirus 
type 8 and parvovirus B19 infections and their 
association with HIV-1 among men who have 
sex with men and injection drug users in Tai-
wan. J Microbiol Immunol Infect 2014; 47: 
 233–238.  
 35 Azadmanesh K, Mohraz M, Kazemimanesh 
M, Aghakhani A, Foroughi M, Banifazl M, 
Eslamifar A, Ramezani A: Frequency and 
genotype of human parvovirus B19 among 
Iranian patients infected with HIV. J Med Vi-
rol 2015; 87: 1124–1129. 
 36 Guiserix J, Ramdane M, Hoarau JM, Finielz P, 
Michault A: Parvovirus B19 and hemodialy-
sis. Nephron 1996; 72: 719. 
 37 Frickhofen N, Abkowitz JL, Safford M, Berry 
JM, Antunez-de-Mayolo J, Astrow A, Cohen 
R, Halperin I, King L, Mintzer D, Cohen B, 
Young NS: Persistent B19 parvovirus infec-
tion in patients infected with human immu-
nodeficiency virus type 1 (HIV-1): a treatable 
cause of anemia in AIDS. Ann Intern Med 
1990; 113: 926–933. 
 38 Chernak E, Dubin G, Henry D, Naides SJ, 
Hodinka RL, MacGregor RR, Friedman HM: 
Infection due to parvovirus B19 in patients in-
fected with human immunodeficiency virus. 
Clin Infect Dis 1999; 20: 170–173. 
 39 Erdman DD, Durigon EL, Wang QY, Ander-
son LJ: Genetic diversity of human parvovirus 
B19: sequence analysis of the VP1/VP2 gene 
from multiple isolates. J Gen Virol 1996; 77: 
 2767–2774. 
 
D
ow
nl
oa
de
d 
by
: 
Ve
rla
g 
S.
 K
AR
G
ER
 A
G
, B
AS
EL
   
   
   
   
   
   
   
   
   
  
17
2.
16
.6
.9
3 
- 2
/6
/2
01
7 
3:
11
:0
8 
PM
